LPAR4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL258032	0.61	6/20
SCHEMBL258094	0.61	6/20
SCHEMBL258118	0.61	6/20
SCHEMBL258136	0.61	6/20
SCHEMBL258161	0.61	6/20
Lysophosphatidic Acid (SCHEMBL1548)	1.00	5/20
Phosphoric Acid (SCHEMBL222057)	0.68	5/20
SCHEMBL45056	0.59	5/20
SCHEMBL250888	0.59	5/20
SCHEMBL496845	0.56	5/20
SCHEMBL370759	0.54	5/20
SCHEMBL40048	0.50	5/20
SCHEMBL303128	0.50	5/20
SCHEMBL482324	0.50	5/20
SCHEMBL21003	0.47	5/20
SCHEMBL501728	0.47	5/20
SCHEMBL608015	0.47	5/20
SCHEMBL88391	0.46	5/20
SCHEMBL570522	0.45	5/20
SCHEMBL226510	0.44	5/20

Clinical trials — most relevant to LPAR4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)	PHASE4	UNKNOWN
Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis	PHASE4	COMPLETED
Montelukast in Parkinson Disease	PHASE2/PHASE3	RECRUITING
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
Fish Oil and Aspirin With Type 2 Diabetes	PHASE2	COMPLETED
Investigation the Effect of Montelukast in COVID-19	PHASE2	UNKNOWN
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Assessment of Coronary Plaque Composition	PHASE1	COMPLETED
Autotaxin (ATX) as a Marker for Breast Cancer	nan	UNKNOWN
The dıagnostıc Value of Serum autotaxın Level ın Colorectal Cancer	nan	COMPLETED
Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease	nan	RECRUITING
The Severe Asthma Research Program III-Boston Clinical Site	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans.	nan	COMPLETED
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study	nan	UNKNOWN
Evaluation of Cascade Screening for Elevated Lipoprotein(a)	nan	ACTIVE_NOT_RECRUITING
Positron Emission Tomography (PET) to Study Brain Signaling	nan	COMPLETED
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness	nan	UNKNOWN
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance	nan	UNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
LDL-Apheresis for FSGS CardioRenal Outcomes	nan	COMPLETED
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies	nan	UNKNOWN
Prognostic Factors Keeping Track for COVID-19 Pneumonia	nan	COMPLETED
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity	nan	NOT_YET_RECRUITING
Leukotrienes Pathway in Chinese Children With Sleep-disordered Breathing	nan	UNKNOWN
Investigation of Lipoxin A4, Annexin A1 and Interleukin-1 Beta Levels in Individuals With Periodontitis.	nan	COMPLETED
In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme	nan	NOT_YET_RECRUITING
Effect of Mechanical Ventilation on Plasma Concentration Level of R-spondin Proteins	nan	COMPLETED
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation	nan	COMPLETED
Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a LPAR4 binder may also engage these)

Protein	Name	Similarity
Q8BLG2	—	1.000	Q8BLG2 →
Q4G072	—	0.996	Q4G072 →
LPAR6	Lysophosphatidic acid receptor 6	0.993	landscape →
Q8BMC0	—	0.989	Q8BMC0 →
Q924T8	—	0.985	Q924T8 →
Q9ESG6	—	0.984	Q9ESG6 →
D4A4Q2	—	0.984	D4A4Q2 →
Q9CPV9	—	0.983	Q9CPV9 →
Q80Z39	—	0.982	Q80Z39 →
D4A7K7	—	0.982	D4A7K7 →
Q2NNR5	—	0.981	Q2NNR5 →
CYSLTR1	Cysteinyl leukotriene receptor 1	0.981	landscape →
Q95N02	—	0.981	Q95N02 →
Q8BFU7	—	0.980	Q8BFU7 →
HCAR2	Hydroxycarboxylic acid receptor 2	0.980	landscape →
Q99JA4	—	0.980	Q99JA4 →
P55086	—	0.980	P55086 →
Q3ZBK9	—	0.980	Q3ZBK9 →
P2RY10	Putative P2Y purinoceptor 10	0.980	landscape →
Q3U507	—	0.979	Q3U507 →
Q9EP66	—	0.979	Q9EP66 →
Q8BG55	—	0.979	Q8BG55 →
F2R	Proteinase-activated receptor 1	0.978	landscape →
Q2HJA4	—	0.978	Q2HJA4 →
Q3SX17	—	0.978	Q3SX17 →
F2RL1	Proteinase-activated receptor 2	0.978	landscape →
GPR174	Probable G-protein coupled receptor 174	0.978	landscape →
P32250	—	0.978	P32250 →
P2RY12	P2Y purinoceptor 12	0.978	landscape →
Q9XSD4	—	0.978	Q9XSD4 →